细胞间粘附分子-1

细胞间粘附分子-1是免疫球蛋白家族的跨膜糖蛋白,是介导细胞与细胞间粘附的粘附分子。近年发现它在肿瘤及其转移方面起重要作用。研究发现:肝癌病人血清中细胞间粘附分子-1明显高于正常人和良性肿瘤病人、有转移的病人高于无转移     

细胞间粘附分子-1与高血压

细胞间黏附是组织结构和形态变化的分子基础之一 ,介导此作用的细胞间黏附分子 1(intercelluaradhensionmolecule 1,ICAM 1)属于免疫球蛋白超家族成员 ,是一种含有 5 0 5个氨基酸的跨膜糖蛋白[1] 。ICAM 1通过与其配件 β2 整合素 -白细胞免疫功能相关抗原 1(LFA 1)和巨噬细胞 1抗原 (Mac 1)结合后 ,介导的细胞黏附在维持机体正常的生理功能和在免疫炎症等疾病发生发展过程中有着重要意义 ,是疾病诊断和监测时有价值的指标[2 ] 。研究发现 ,ICAM 1的异常表达涉及多种心血管疾病[1] 。高血压是我国最常见的心血管疾病之一 …     

细胞间粘附分子-1与高血压

细胞间黏附是组织结构和形态变化的分子基础之一,介导此作用的细胞间黏附分子-1(intercelluar adhension molecule-1,ICAM-1)属于免疫球蛋白超家族成员,是一种含有505个氨基酸的跨膜糖蛋白[1].ICAM-1通过与其配件β2整合素-白细胞免疫功能相关抗原-1(LFA-1)和巨噬细胞-1抗原(Mac-1)结合后,介导的细胞黏附在维持机体正常的生理功能和在免疫炎症等疾病发生发展过程中有着重要意义,是疾病诊断和监测时有价值的指标[2].研究发现,ICAM-1的异常表达涉及多种心血管疾病[1].     

细胞间粘附分子-1与慢性肝病

病毒感染、毒物及自身免疫等多种因素均可引起肝脏慢性炎症、损伤,进而发展为肝纤维化甚至肝硬化。然而,对于慢性肝病的病程监测及疗效评价,人们一直缺乏特异的非创伤性指     

糖尿病患者血清可溶性细胞间粘附分子-1和可溶性血管细胞粘附分子-1变化的研究

目的　研究糖尿病患者血清可溶性细胞间粘附分子 - 1(s ICAM- 1)和可溶性血管细胞粘附分子 - 1(s VCAM- 1)水平的变化。方法　应用酶联免疫吸附法 (EL ISA)检测了 18例 1型糖尿病和 47例 2型糖尿病患者及 2 0例健康对照者的血清 s ICAM- 1、s VCAM- 1以及甘油三酯 (TG)水平。结果　 1血清 s ICAM- 1和 s VCAM- 1水平 ,1型、2型糖尿病患者组均显著高于健康对照组 (P<0 .0 5～ 0 .0 1) ,2型糖尿病有微血管病变组又高于无微血管病变组 (P<0 .0 5～ 0 .0 1) ,1型糖尿病与 2型糖尿病组之间无显著性差异 ;2血清 s VCAM- 1水平 ,2型糖尿病的高甘油三酯血症组 (A组 )、高甘油三酯血症合并高血压组 (B组 )高于单纯高血压组 (C组 )和甘油三酯、血压正常组 (D组 ) (P均 <0 .0 5 ) ;3 1型糖尿病和 2型糖尿病患者血清 s ICAM- 1和 s VCAM- 1之间均呈正相关关系 (r=0 .83、0 .5 3,P均 <0 .0 1)。结论　 12型糖尿病患者血清 s VCAM- 1升高与高甘油三酯血症有关 ;2血清 s ICAM- 1和 s VCAM- 1参与了糖尿病微血管病变的发病过程 ,并可作为糖尿病病情变化的监测指标     

细胞间粘附分子-1与胃肠道恶性肿瘤

细胞间粘附分子-1(ICAM-1)是一种分子量为80-110kD的单链糖蛋白,通过与其配体淋巴细胞功能相关抗原-1的相互作用,介导了异型细胞及细胞-胞外基质间的粘附,与恶性肿瘤的侵袭活动有关,并影响了体内免疫系统对肿瘤细胞的免疫监视和免疫防御作用。本文就ICAM-1在胃癌及结肠癌生长、浸润和转移过程中的作用作一综述,并展望了ICAM-1的临床应用前景。     

可溶性血管细胞粘附分子-1与糖尿病并发症

粘附分子在糖尿病及其并发症的发生过程中起着重要的作用 ,粘附分子种类繁多 ,包括选择素家族、免疫球蛋白家族、整合素家族、钙依赖粘附素家族等。而可溶性血管细胞粘附分子 1(sVCAM 1)为免疫球蛋白家族成员之一 ,主要表达于激活的内皮细胞、平滑肌细胞和组织巨噬细胞 ,参与单核细胞、淋巴细胞与内皮细胞的粘附及聚集。其在糖尿病患者体内较正常人明显增高 ,并且与糖尿病并发症密切相关。现结合文献对sVCAM 1与糖尿病并发症的关系综述如下。1　sVCAM 1与糖尿病大血管并发症大血管病变是糖尿病非特异性并发症 ,其基本病理变化为动脉粥…     

细胞间粘附分子-1在肝病中的表达

细胞间粘附分子-1(ICAM-1)在炎症细胞因子刺激下,在病毒性肝炎、酒精性肝病、肝细胞癌(HCC)和自身免疫性肝病中表达水平明显增高,其表达程度与炎症程度呈正相关,与肝组织病变及病变组织学分级均有关;ICAM-1表达水平的高低可能影响干扰素对慢性病毒性肝炎的治疗;ICAM-1表达与肿瘤的大小、进展、转移也有关,并随病情的缓解而下降。促进ICAM-1表达的细胞因子有IFN-γ、TNF-α、IL-1和HBV X蛋白。     

细胞间粘附分子-1在肺部炎症中的作用

细胞间粘附分子-1,又名CD_(54)是一种重要的细胞间表面粘附分子,属于免疫球蛋白超家族一员。它可与整合素家族成员及鼻病毒结合,参与各种炎症反应,本文就其细胞分布、表达调节及在肺部炎症中的作用及相应临床应用作一综述。     

A clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with gastric cancer

Ａｃｌｉｎｉｃａｌｅｖａｌｕａｔｉｏｎｏｆｓｅｒｕｍｃｏｎｃｅｎｔｒａｔｉｏｎｓｏｆｉｎｔｅｒｃｅｌｕｌａｒａｄｈｅｓｉｏｎｍｏｌｅｃｕｌｅ１ｉｎｐａｔｉｅｎｔｓｗｉｔｈｇａｓｔｒｉｃｃａｎｃｅｒＬＩＵＹｏｎｇＺｈｏｎｇ,ＣＨＥＮＢｉｎａｎｄＳＨ...     

血清可溶性细胞间黏附分子-1在皮肌炎合并间质性肺病患者中的意义研究

目的 探讨血清可溶性细胞间黏附分子1 (sICAM-1)在皮肌炎合并间质性肺病(ILD)患者中的意义.方法 回顾性分析中国医科大学附属第一医院2018年1月至2020年2月50例确诊为皮肌炎的患者,按是否合并ILD分为ILD组和非ILD组.收集研究对象的临床资料并使用酶联免疫吸附测定(ELISA)法测量血清sICAM-...     

系统性红斑狼疮患者血清可溶性黏附分子的检测

目的检测系统性红斑狼疮(SLE)患者血清黏附分子中可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性细胞间黏附分子-1(sICAM-1)的水平,并探讨其临床意义。方法采用酶联免疫吸附试验(ELISA)法,检测30名健康人和60例SLE患者血清sVCAM-1、sICAM-1水平,以分析其与SLE活动性变化关系。结果①SLE患者血清sVCAM-1平均水平为2342ng/ml,显著高于正常人对照组1240ng/ml(P<0.001)。②SLE患者中血清sICAM-1平均水平为802ng/ml,显著高于正常人对照组626ng/ml(P<0.001)。③SLE患者中,血清sVCAM-1水平活动期高于稳定期(P<0.05),sICAM-水平活动期高于稳定期(P<0.05)。④SLE组血清sVCAM-1和sICAM-1水平与SLE病情活动指数(SLEDAI)、抗dsDNA抗体水平及尿蛋白的发生呈正相关,与血清补体C3水平呈负相关。结论sVCAM-1,sICAM-1可能参与SLE发病机制。     

通心络超微粉对高脂饮食兔胸主动脉NF-κB、胞间黏附分子1及血管细胞黏附分子1表达的影响

目的探讨通心络超微粉对高脂饮食兔胸主动脉NF-κB、胞间黏附分子1（ICAM-1）及血管细胞黏附分子1（VCAM-1）表达的影响。方法健康雄性新西兰白兔32只,随机分为空白对照组、模型组、阿托伐他汀组、通心络组四组。空白对照组,饲以普通饲料;模型组,饲以高脂饲料;阿托伐他汀组,饲以高脂饲料同时阿托伐他汀（3mg·kg^-1·d^-1）灌胃;通心络组,饲以高脂饲料同时通心络超微粉（0．31g·kg^-1·d^-1）灌胃,连续给药,于6周末免疫组织化学染色法检测主动脉壁中NF-κB核转位情况、ICAM-1及VCAM-1蛋白表达情况,RT—PCR法检测ICAM-1 mRNA及VCAM-1 mRNA表达。结果与空白对照组相比,模型组家兔主动脉壁中NF—KB核转位明显增加。ICAM-1、VCAM-1基因及蛋白表达明显增多（P〈O．01）。与模型组相比,通心络组与阿托伐他汀组家兔主动脉壁中NF-κB核转位明显减少、ICAM-1、VCAM-1基因及蛋白表达明显减少（P〈0．01或P〈0．05）,通心络组显著少于阿托伐他汀组（P〈0．01）。结论通心络超微粉通过抑制NF-κB核转位进而降低ICAM-1、VCAM-1基因及蛋白表达,减轻动脉粥样硬化病理改变。     

Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease

Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1, sCD106) were significantly elevated in patients with Hodgkin's disease (HD) (n = 101) compared to controls (n = 31) (P < 0.0001). sVCAM-1 correlated with histology, stage, B-symptoms, and prognostic markers (sICAM-1, sCD30, sIL-2R, LDH). sVCAM-1, sICAM-1 and sCD30 added independent prognostic information for both disease-free and overall survival. 14 biopsies from 13 patients with HD were immunostained for VCAM-1 and ICAM-1. The vascular endothelium stained positive for VCAM-1 in 10/12 evaluable biopsies and for ICAM-1 in all evaluable biopsies. A stromal expression of both adhesion molecules precluded a precise evaluation of HRS-cells. This led us to investigate VCAM-1 (and ICAM-1) expression in six Hodgkin cell lines (HDLM-2, L428, L540, L591, DEV, KM-H2). Two cell lines stained positive for VCAM-1 (HDLM-2, L591). All cell lines stained positive for ICAM-1. sVCAM-1 is a new prognostic marker in HD; its predictive power equals or surpasses that of sCD30 and sICAM-1. Furthermore, two Hodgkin cell lines stained positive for VCAM-1. This indicates that VCAM-1 may be expressed by some HD tumour cells in vivo.     

黏附分子在阻塞性睡眠呼吸暂停低通气综合征合并高血压发病中的作用

目的 探讨细胞黏附分子在阻塞性睡眠呼吸暂停低通气综合征(OSAHS)合并高血压(HT)发病中的作用。方法 应用酶联免疫吸附测定(ELISA)方法检测30例OSAHS血压正常患者(OSAHS组)、30例OSAHS合并高血压患者(OSAHS HT组)及30名健康者(正常对照组)血清中可溶性胞间黏附分子1(ICAM-1)、血管细胞黏附分子1(VCAM-1)和L-选择素的含量。结果 OSAHS HT组及OSAHS组患者血清可溶性ICAM-1[分别为(601±406)μg/,L、(513±244)μg/L]、VCAM-1含量[分别为(578±176)μg/L、(480±144)μg/L]均明显高于正常对照组[分别为(355±119)μg/L、(310±163)μg/L,q值分别为4.78,3.07;9.09,5.76,P<0.01],差异有显著性;而L-选择素与对照组相比,差异无显著性(P>0.05);OSAHS HT组的VCAM-1明显高于OSAHS组(q值为3.32,P<0.05),差异有显著性;ICAM-1水平与睡眠呼吸暂停低通气指数(AHI)及微觉醒指数呈明显的正相关(r=0.465,P<0.01,r=0.226,P<0.05);与最低血氧饱和度呈明显的负相关(r=-0.368,P<0.01)。结论 血清ICAM-1、VCAM-1水平的升高是OSAHS患者高血压发病的重要危险因子之一。     

Phase tissue intercellular adhesion molecule-1 expression in nude mice human liver cancer metastasis model

AIM To study the phase cancer tissue intercellular adhesion molecule-1 (ICAM-1) expression of human cancer metastasis model in nude mice, and to analyze the relationship between ICAM-1 expression and the metastasis and recurrence of hepatocellular cancinoma (HCC).METHODS HCC tissues from liver cancer metastasis model in nude mice (LCI-D20) was orthotopically implanted, and ICAM-1 expression in HCC tissues at different growing time were detected by immunodot blot. Tumor size, intrahepatic and extrahepatic metastasis foci were observed by naked eyes and under light microscope.RESULTS ICAM-1 was positively correlated to the tumor growing time (r=0.88, P＜0.01) and tumor size r=0.5, P＜0.05). It was higher in metastatic HCC than in nonmetastatic HCC (8.24±0.95 vs 3.03±0.51, P＜0.01). ICAM-1 content in cancer tissues increased suddenly after metastasis occurred and then maintained in a high level. ICAM-1 was also higher in multimetastasis group than in monometastasis group (10.05±1.17 vs 5.48±0.49, P＜0.05).CONCLUSION Tissue ICAM-1 could predict not only the metastasis of human liver cancer metastasis model in nude mice early and sensitively, but also the metastasis degree. So tissue ICAM-1 may be a potential index indicating the status of metastasis of HCC patients.     

Elevated serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) closely reflect tumour burden in chronic B-lymphocytic leukaemia

The present study is the first to report elevated serum levels of soluble (s)VCAM-1 in B-cell chronic lymphocytic leukaemia (B-CLL). A large cohort of 106 untreated patients was studied. sVCAM-1 was compared to known prognostic serum markers (soluble (s)ICAM-1; lactate dehydrogenase, LDH; sCD23; thymidine kinase, TK; β2microglobulin, β2m). The serum levels of sVCAM-1 reflected tumour burden as expressed by Binet/Rai stages more closely than any other marker. sVCAM-1 also reflected the kinetics of the disease as revealed by lymphocyte doubling time. sVCAM-1 was the only one of the studied markers which showed elevated levels in smouldering disease compared to controls. sVCAM-1, sICAM-1 and sCD23 (but not LDH, TK, β2m) separated smouldering from non-smouldering B-CLL. Only sICAM-1, sCD23 and TK added independent prognostic information for survival to that of stage and lymphocyte doubling time.
The expression of both adhesion molecules was examined in lymph node and splenic specimens. VCAM-1 and ICAM-1 were overexpressed by vascular endothelium and stroma, but the intensity of expression correlated poorly with serum levels of the soluble molecules.
In conclusion, serum levels of sVCAM-1 correlated with tumour burden and other prognostic markers in B-CLL. VCAM-1 was overexpressed in tumour tissue as was ICAM-1. sVCAM-1 could prove a valuable marker in younger early-stage patients eligible for therapeutic trials.     

血清可溶性细胞间黏附分子1、透明质酸水平与Graves眼病疾病活动性之间的关系

探讨可溶性细胞间黏附分子1( sICAM-1)和透明质酸(HA)能否反映Graves眼病(GO)的疾病活动性.用ELISA方法检测48例GO患者(眼病组)的sICAM-1、HA水平,同时检测30例单纯Graves甲状腺功能亢进患者作为对照组.与对照组相比,眼病组的血清sICAM-1、HA水平明显增高(P＜0.05);且眼病组活动期的血清sICAM-1、HA水平明显高于稳定期(P＜0.05).Pearson相关性分析显示眼病组的血清sICAM-1、HA水平均与眼病活动分数(CAS)呈显著正相关(r=0.53,P＜0.01;r=0.46,P＜0.01),且sICAM-1与HA亦呈正相关(r=0.31,P＜0.05).GO患者外周血sICAM-1、HA水平可作为评价GO活动性的指标.     

关于高血压患者血清HGF、sICAM-1水平的研究（英文）

目的：探讨高血压患者血清肝细胞生长因子（HGF）,可溶性细胞间黏附分子-1（sICAM-1）水平的变化及其意义。方法：选择59例高血压患者,其中高血压1级组20例,高血压2级组19例,高血压3级组20例,并选择30例健康体检者作为正常对照组。用酶联免疫双抗体夹心法检测各组血清HGF和sICAM-1浓度,并进行比较。结果：与正常对照组相比,高血压患者血清HGF[（641.65±142.90）pg/ml比（998.15±241.38）pg/ml]、sI-CAM-1[（161.70±32.36）ng/ml比（327.17±31.28）ng/ml]水平明显升高（P〈0.01）,血压越高,其变化越显著（P〈0.01）,HGF浓度与sICAM-1浓度呈正相关（r=0.317,P〈0.01）。结论：HGF与sICAM-1可能参与了高血压的发病过程,而且HGF在高血压内皮细胞损伤的修复中可能具有重要作用。